StockData
Ocular Therapeutix, Inc logo

Ocular Therapeutix, Inc (OCUL) stock

OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3011% above fair value
$6.02+0.01 (+0.17%)

Close on Nov 17, 2026Market cap $1.32BP/E –Yield –

Ocular Therapeutix total assets

Total assets on the balance sheet at the end of each period.

Ocular Therapeutix's total assets was $671.32M at Jun 30, 2026. For fiscal 2025 it was $808.06M, up 76.5% from the year before. Over ten years it grew 22.0% a year on average. The highest annual figure on record is $808.06M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$808.06M+76.5%
FY2024Dec 31, 2024$457.94M+81.7%
FY2023Dec 31, 2023$252.06M+68.8%
FY2022Dec 31, 2022$149.29M-27.1%
FY2021Dec 31, 2021$204.89M-21.8%
FY2020Dec 31, 2020$261.86M+232.6%
FY2019Dec 31, 2019$78.74M+7.8%
FY2018Dec 31, 2018$73.04M+31.8%
FY2017Dec 31, 2017$55.43M-26.0%
FY2016Dec 31, 2016$74.94M-32.1%
FY2015Dec 31, 2015$110.31M+41.1%
FY2014Dec 31, 2014$78.19M+308.4%
FY2013Dec 31, 2013$19.15M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$671.32M+48.7%
Q1 FY2026Mar 31, 2026$732.53M+80.5%
Q4 FY2025Dec 31, 2025$808.06M+76.5%
Q3 FY2025Sep 30, 2025$410.88M-16.2%
Q2 FY2025Jun 30, 2025$451.33M-12.7%
Q1 FY2025Mar 31, 2025$405.92M-24.7%
Q4 FY2024Dec 31, 2024$457.94M+81.7%
Q3 FY2024Sep 30, 2024$490.37M+202.0%
Q2 FY2024Jun 30, 2024$517.09M+321.9%
Q1 FY2024Mar 31, 2024$538.95M+319.2%
Q4 FY2023Dec 31, 2023$252.06M+68.8%
Q3 FY2023Sep 30, 2023$162.38M+2.4%
Q2 FY2023Jun 30, 2023$122.56M-29.2%
Q1 FY2023Mar 31, 2023$128.57M-31.5%
Q4 FY2022Dec 31, 2022$149.29M-27.1%
Q3 FY2022Sep 30, 2022$158.58M-27.2%
Q2 FY2022Jun 30, 2022$173.07M-25.0%
Q1 FY2022Mar 31, 2022$187.62M-22.8%
Q4 FY2021Dec 31, 2021$204.89M-21.8%
Q3 FY2021Sep 30, 2021$217.74M+121.7%
Q2 FY2021Jun 30, 2021$230.71M+115.1%
Q1 FY2021Mar 31, 2021$243.04M+233.6%
Q4 FY2020Dec 31, 2020$261.86M+232.6%
Q3 FY2020Sep 30, 2020$98.22M+10.7%
Q2 FY2020Jun 30, 2020$107.26M+19.5%
Q1 FY2020Mar 31, 2020$72.86M-28.2%
Q4 FY2019Dec 31, 2019$78.74M+7.8%
Q3 FY2019Sep 30, 2019$88.71M+26.2%
Q2 FY2019Jun 30, 2019$89.74M+27.4%
Q1 FY2019Mar 31, 2019$101.49M+32.3%
Q4 FY2018Dec 31, 2018$73.04M+31.8%
Q3 FY2018Sep 30, 2018$70.27M+9.1%
Q2 FY2018Jun 30, 2018$70.46M-11.6%
Q1 FY2018Mar 31, 2018$76.69M-15.4%
Q4 FY2017Dec 31, 2017$55.43M-26.0%
Q3 FY2017Sep 30, 2017$64.40M-21.8%
Q2 FY2017Jun 30, 2017$79.68M–
Q1 FY2017Mar 31, 2017$90.70M–
Q4 FY2016Dec 31, 2016$74.94M–
Q3 FY2016Sep 30, 2016$82.35M–

More Ocular Therapeutix figures

See a number that looks wrong?